BP-897 is a drug used in scientific research which acts as a potent selective dopamine D3receptorpartial agonist with an in vitrointrinsic activity of ~0.6 and ~70x greater affinity for D3 over D2 receptors and is suspected to have partial agonist or antagonist activity in vivo.[1] It has mainly been used in the study of treatments for cocaine addiction.[2][3][4][5][6][7][8] A study comparing BP-897 with the potent, antagonistic, and highly D3 selective SB-277,011-A found, "SB 277011-A (1–10 mg/kg) was able to block cue-induced reinstatement of nicotine-seeking, indicating that DRD3 selective antagonism may be an effective approach to prevent relapse for nicotine. In contrast, BP 897 did not block the cue-induced reinstatement of nicotine-seeking or nicotine-taking under the FR5 schedule."[9]
References
↑"Selective inhibition of cocaine-seeking behaviour by a partial dopamine D3 receptor agonist". Nature400 (6742): 371–375. July 1999. doi:10.1038/22560. PMID10432116.
↑"The D3R partial agonist, BP 897, attenuates the discriminative stimulus effects of cocaine and D-amphetamine and is not self-administered". Behavioural Pharmacology12 (1): 1–11. February 2001. doi:10.1097/00008877-200102000-00001. PMID11270507.
↑"Effects of a dopamine D3 receptor ligand, BP 897, on acquisition and expression of food-, morphine-, and cocaine-induced conditioned place preference, and food-seeking behavior in rats". Neuropsychopharmacology28 (11): 1903–1915. November 2003. doi:10.1038/sj.npp.1300276. PMID12915863.
↑"Effect of the D3 dopamine receptor partial agonist BP897 [N-[4-(4-(2-methoxyphenyl)piperazinyl)butyl]-2-naphthamide] on L-3,4-dihydroxyphenylalanine-induced dyskinesias and parkinsonism in squirrel monkeys". The Journal of Pharmacology and Experimental Therapeutics311 (2): 770–777. November 2004. doi:10.1124/jpet.104.071142. PMID15226382.
↑"18F-Labeled FAUC 346 and BP 897 derivatives as subtype-selective potential PET radioligands for the dopamine D3 receptor". ChemMedChem3 (5): 788–793. May 2008. doi:10.1002/cmdc.200700327. PMID18306190.
↑"The selective dopamine D3 receptor antagonist SB 277011-A, but not the partial agonist BP 897, blocks cue-induced reinstatement of nicotine-seeking". The International Journal of Neuropsychopharmacology13 (2): 181–190. March 2010. doi:10.1017/S1461145709991064. PMID19995481.